ORIC Pharmaceuticals, Inc.
ORICHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, ORIC Pharmaceuticals, Inc. focuses on Biotechnology services and products. ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. The $1.31B market capitalization puts ORIC squarely in small-cap range for its industry. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study.
Market Cap
$1.31B
Beta
0.99
P/E (TTM)
—
P/E (Fwd)
-7.81
EPS (TTM)
$-1.30
EPS (Fwd)
$-1.61
ROE
-39.8%
ROA
-26.0%
Cash
$264.8M
Total Debt
$6.0M
Free CF
-$68.8M
52W Change
17.9%
Annual Financials
Cash vs Debt
Where ORIC stands vs its 150-day and 200-day moving averages
As of the August 27, 2026 close, ORIC finished 29.40% above its 150-day moving average ($10.75) and 30.73% above its 200-day moving average ($10.64). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ORIC overbought or oversold?
At the August 27, 2026 close, ORIC's RSI(14) was 59.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
ORIC Pharmaceuticals, Inc. holds $264.8M in cash against $6.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$68.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -39.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, ORIC has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence ORIC Pharmaceuticals, Inc.'s trajectory.